308 related articles for article (PubMed ID: 11165113)
1. Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents.
Gradelski E; Kolek B; Bonner DP; Valera L; Minassian B; Fung-Tomc J
Int J Antimicrob Agents; 2001 Feb; 17(2):103-7. PubMed ID: 11165113
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of bacterial isolates to gatifloxacin and ciprofloxacin from clinical trials 1997-1998.
Huczko E; Conetta B; Bonner D; Valera L; Stickle T; Macko A; Fung-Tomc J
Int J Antimicrob Agents; 2000 Dec; 16(4):401-5. PubMed ID: 11118848
[TBL] [Abstract][Full Text] [Related]
3. Activity of gatifloxacin against strains resistant to ofloxacin and ciprofloxacin and its ability to select for less susceptible bacterial variants.
Fung-Tomc J; Gradelski E; Huczko E; Minassian B; Bonner DP
Int J Antimicrob Agents; 2001 Jul; 18(1):77-80. PubMed ID: 11463531
[TBL] [Abstract][Full Text] [Related]
4. Comparative killing rates of gatifloxacin and ciprofloxacin against 14 clinical isolates: impact of bacterial strain and antibiotic concentration.
Pendland SL; Neuhauser MM; Garey KW; Prause JL; Jung R
Diagn Microbiol Infect Dis; 2002 Sep; 44(1):59-61. PubMed ID: 12376032
[TBL] [Abstract][Full Text] [Related]
5. Comparative antimicrobial activity of gatifloxacin with ciprofloxacin and beta-lactams against gram-positive bacteria.
Bassetti M; Dembry LM; Farrel PA; Callan DA; Andriole VT
Diagn Microbiol Infect Dis; 2001 Nov; 41(3):143-8. PubMed ID: 11750168
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.
Otani T; Tanaka M; Ito E; Kurosaka Y; Murakami Y; Onodera K; Akasaka T; Sato K
Antimicrob Agents Chemother; 2003 Dec; 47(12):3750-9. PubMed ID: 14638477
[TBL] [Abstract][Full Text] [Related]
7. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2004). I. Susceptibility distribution].
Kumamoto Y; Tsukamoto T; Matsukawa M; Kunishima Y; Hirose T; Shigeta S; Yamaguti O; Ishibashi K; Suzutani T; Yoshida H; Imafuku Y; Murai M; Watanabe K; Kobayashi Y; Uchida H; Matsuda S; Sato S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Furuya N; Deguchi T; Ishihara S; Ooe H; Oka T; Kitamura M; Fukuhara Y; Kamidono S; Arakawa S; Kumon H; Monden K; Matsumoto T; Muratani T; Naito S; Egashira T; Konishi T; Kohno S; Hirakata Y; Kondo A; Matsuda J; Nakano M
Jpn J Antibiot; 2006 Jun; 59(3):177-200. PubMed ID: 16913404
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity and accumulation of moxifloxacin in quinolone-susceptible bacteria.
Piddock LJ; Jin YF
J Antimicrob Chemother; 1999 May; 43 Suppl B():39-42. PubMed ID: 10382874
[TBL] [Abstract][Full Text] [Related]
9. [Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
Matsuzaki K; Watabe E; Yoshimori K; Shikano M; Sato Y; Hasegawa M; Kobayashi I
Jpn J Antibiot; 2002 Dec; 55(6):800-7. PubMed ID: 12621734
[TBL] [Abstract][Full Text] [Related]
10. [Comparative in vitro activity of garenoxacin (BMS-284756). Sentry program, Spain (1999-2000)].
Loza E; Cantón R; Pascual A; Tubau F; Morosini MI; Almaraz F; Perea E; Martín R; Jones RN; Baquero F
Enferm Infecc Microbiol Clin; 2003 Oct; 21(8):404-9. PubMed ID: 14525705
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms.
Dawis MA; Isenberg HD; France KA; Jenkins SG
J Antimicrob Chemother; 2003 May; 51(5):1203-11. PubMed ID: 12697632
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
Dalhoff A; Petersen U; Endermann R
Chemotherapy; 1996; 42(6):410-25. PubMed ID: 8957575
[TBL] [Abstract][Full Text] [Related]
13. Synergy of fluoroquinolones with other antimicrobial agents.
Neu HC
Rev Infect Dis; 1989; 11 Suppl 5():S1025-35. PubMed ID: 2505355
[TBL] [Abstract][Full Text] [Related]
14. The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
Wise R; Brenwald NP; Andrews JM; Boswell F
J Antimicrob Chemother; 1997 Apr; 39(4):447-52. PubMed ID: 9145816
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.
Sweeney MT; Zurenko GE
Antimicrob Agents Chemother; 2003 Jun; 47(6):1902-6. PubMed ID: 12760865
[TBL] [Abstract][Full Text] [Related]
16. Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose.
Boy D; Well M; Kinzig-Schippers M; Sörgel F; Ankel-Fuchs D; Naber KG
Int J Antimicrob Agents; 2004 Mar; 23 Suppl 1():S6-16. PubMed ID: 15037323
[TBL] [Abstract][Full Text] [Related]
17. Microbiology at first visit of moderate-to-severe diabetic foot infection with antimicrobial activity and a survey of quinolone monotherapy.
Tascini C; Piaggesi A; Tagliaferri E; Iacopi E; Fondelli S; Tedeschi A; Rizzo L; Leonildi A; Menichetti F
Diabetes Res Clin Pract; 2011 Oct; 94(1):133-9. PubMed ID: 21824673
[TBL] [Abstract][Full Text] [Related]
18. Postantibiotic effects of E-4868 and OPC-17116.
Sanford MD; Jones RN
J Antimicrob Chemother; 1993 Dec; 32(6):916-7. PubMed ID: 8144440
[No Abstract] [Full Text] [Related]
19. In-vitro and in-vivo activities of DW-116, a new fluoroquinolone.
Choi KH; Hong JS; Kim SK; Lee DK; Yoon SJ; Choi EC
J Antimicrob Chemother; 1997 Apr; 39(4):509-14. PubMed ID: 9145824
[TBL] [Abstract][Full Text] [Related]
20. Activity of amikacin, ertapenem, ciprofloxacin and levofloxacin alone and in combination against resistant nosocomial pathogens by time-kill.
Hosgor-Limoncu M; Ermertcan S; Tasli H; Yurtman AN
West Indian Med J; 2008 Mar; 57(2):106-11. PubMed ID: 19565951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]